Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia in Children
NCT03939637Phase 3Completed
- Sponsor
- Baylor College of Medicine
- Start
- May 2019
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of eltrombopag in immune thrombocytopenia (ITP) (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Proportion of Patients With a Platelet Response at 12 weeks. Started May 2019; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03939637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939637.